Millions of adults over age 50 struggle each year with vision loss caused by damage to the retina or common macular degeneration.
Physics researchers at The University of Texas at Arlington have developed a new platform that uses ultrafast near-infrared lasers to deliver gene therapy to damaged areas of the retina to enable vision restoration in patients with photo-degenerative diseases.
“Most therapies focus on slowing down or halting degeneration but cannot target already-damaged areas of the retina,” said Samarenda Mohanty, assistant professor of physics and head of UTA’s Biophysics and Physiology Group, who led the research. “Our capacity to specifically target these damaged areas cell by cell opens up a new world of possibilities for vision restoration.”
Mohanty demonstrated the effectiveness of the new method in a recent article published by the Nature journal Light: Science & Applications. In his study, Mohanty and his team compared their ultrafast near-infrared laser-based method of delivering genes with the popular non-viral chemical gene delivery system known as lipofection.
The laser-based method creates a transient sub-mircometer hole that allows the gene for light-sensitive proteins, or opsins, to permeate into the damaged retinal cell. The genes are then activated to produce the opsins, which attach to the cell membrane and convert external light into the photocurrent signals that are basis of sight.
In Mohanty’s experiments, the laser-based method gave better results than chemical gene delivery in terms of the amount of opsins produced and the number expressed on the membrane of the cell. It was also able to target cells one by one where the chemical gene delivery system cannot be that specific.
Furthermore, the laser-based method was also able to effectively deliver large packages of genes encoding a wide spectrum of colors to damaged retinal cells, which could enable broadband vision restoration in patients with photo-degenerative diseases.
With aging populations in many countries, the number of macular degeneration sufferers is expected to reach 196 million worldwide by 2020 and increase to 288 million by 2040, according to The Lancet.
The Latest on: Macular Degeneration
via Google News
The Latest on: Macular Degeneration
- Allergan/AbbVie’s Macular Degeneration Drug Rejected by FDAon June 26, 2020 at 9:59 pm
The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.
- FDA issues CRL to wet AMD drug from Allergan, Molecular Partnerson June 26, 2020 at 4:46 pm
The FDA sent a complete response letter (CRL) to Allergan plc, an Abbvie Inc. company, and Molecular Partners AG, of Zurich, Switzerland, regarding the BLA for abicipar pegol, their VEGF-A ...
- Eye Inflammation Dooms AbbVie Wet AMD Drug to an FDA Rejectionon June 26, 2020 at 3:14 pm
The FDA has rejected an investigational AbbVie drug for the “wet” form of age-related macular degeneration, dealing a setback to the company’s bid to ...
- FDA Rejects AbbVie's Macular Degeneration Drug Abicipar Pegolon June 26, 2020 at 3:11 pm
The drug, which AbbVie gained in its acquisition of Allergan, was supposed to be a growth driver for the company.
- Management and Visual Outcomes of Acute Bacterial Endophthalmitis Following Intravitreal Injection of Contaminated Bevacizumab in a Single Dayon June 26, 2020 at 12:19 pm
BACKGROUND AND OBJECTIVE:Bevacizumab requires compounding for off-label intravitreal injection, thus creating a risk of possible contamination during preparation.PATIENTS AND METHODS:This ...
- Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drugon June 26, 2020 at 7:29 am
The U.S. district attorney for Massachusetts filed suit against the drugmaker this week, alleging that it paid tens of millions in kickbacks through a copay foundation for Eylea, a drug used to treat ...
- AbbVie's Eye Disorder Candidate Gets Complete Response Letteron June 26, 2020 at 6:40 am
AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.
- Seniors in low-income housing live in fear of COVID infectionon June 26, 2020 at 3:30 am
Davetta Brooks, 75, who has heart failure, a fractured hip and macular degeneration, is afraid. Conditions in her low-income senior building on Chicago's Near West Side — the Congressman George W.
- AbbVie's Allergan, Molecular Partners hit by FDA eye drug rejectionon June 26, 2020 at 12:36 am
AbbVie is learning that this week after its buyout of Allergan has seen, just a month after finalizing the deal with the Federal Trade Commission’s blessing, that one of the first drugs it might have ...
- Macular Degeneration Treatment Market to Proliferate at a Healthy CAGR of 7.3% by 2027on June 23, 2020 at 2:53 am
The global Macular Degeneration Treatment Market size is expected to reach USD 11.4 billion by 2027, at a significant growth rate of 6.6 % during the forecasted period 2020 to 2027. The market report ...
via Bing News